```html

Jerusalem Disease (Leprosy, Borderline Type) – A Comprehensive Medical Guide

Overview

Jerusalem disease is a historic name for the **borderline form of leprosy** (also called borderline leprosy or BB leprosy). It belongs to the spectrum of Hansen’s disease, which is caused by the bacterium Mycobacterium leprae. Borderline leprosy lies between the tuberculoid (paucibacillary) and lepromatous (multibacillary) poles, showing features of both and a tendency to shift toward one pole or the other over time.

• Who it affects: Anyone can be infected, but the disease is most common in adults aged 20‑50 years, with a slight male predominance (≈1.3 : 1). Genetic susceptibility, close household contact with an untreated case, and living in areas of endemic transmission increase risk.
• Global prevalence: According to the World Health Organization (WHO), there were ~ 202,256 new leprosy cases reported worldwide in 2022, with ~ 16 % classified as borderline forms. The disease remains endemic in parts of South‑East Asia, sub‑Saharan Africa, and the Americas, especially Brazil, India, and Indonesia.<sup>1</sup>
• Why the name “Jerusalem disease”? The term dates back to the 19th‑century description of a leprosy variant that was thought to be particularly prevalent among pilgrims traveling to Jerusalem. Modern taxonomy prefers “borderline leprosy,” but the historic name is still encountered in older literature.

Symptoms

Borderline leprosy presents a mixed picture. Skin lesions, nerve involvement, and systemic signs may fluctuate, making early recognition essential.

Skin Manifestations

• Annular or irregular plaques: Red‑brown, slightly raised edges with a central flattening; sizes range from a few millimetres to several centimetres.
• Hypopigmented macules: Lighter‑than‑surrounding skin that may become numb.
• Hair loss (alopecia) within lesions: Often patchy.
• Loss of sensation: Decreased temperature, pain, or light touch over the lesion—one of the hallmark signs of leprosy.
• Cool, dry skin: Affected areas may feel cooler than adjacent normal skin.

Nerve Involvement

• Peripheral neuropathy: Thickening of peripheral nerves (especially ulnar, median, common peroneal, and posterior tibial nerves).
• Motor weakness: Claw‑hand or foot drop due to motor fiber loss.
• Sensory loss: Numbness that predisposes to injuries, burns, or secondary infections.
• Neuropathic pain: Burning or tingling sensations.

Systemic Features

• Low‑grade fever or malaise (occasionally).
• Enlarged lymph nodes in advanced cases.
• Rare involvement of eyes (iridocyclitis) or nasal mucosa (chronic rhinitis).

Key Distinguishing Points for Borderline Type

• Lesions are more numerous than in tuberculoid leprosy but fewer than in lepromatous disease.
• Both hypopigmented and erythematous lesions coexist.
• Partial loss of sensation—some lesions retain feeling while others are anesthetic.
• Variable bacterial load (often moderate), detectable on skin smears in many patients.

Causes and Risk Factors

Leprosy is an infectious disease caused exclusively by Mycobacterium leprae (or the closely related M. lepromatosis).

Transmission

• Prolonged, close contact with an untreated patient—most likely via nasal droplets or skin‑to‑skin contact.
• Environmental reservoirs (e.g., armadillos in the southern United States) can infect humans, though this is rare for borderline disease.

Risk Factors

• Genetic susceptibility: Certain HLA types (e.g., HLA‑DR2, HLA‑DR3) are associated with a higher risk of progression after exposure.
• Living conditions: Overcrowded housing, poor ventilation, and limited access to health care increase exposure risk.
• Immunologic status: Borderline leprosy reflects a moderate cell‑mediated immune response—neither strong (tuberculoid) nor absent (lepromatous).
• Age and sex: Peak incidence in young to middle‑aged adults; slight male predominance.
• Socio‑economic factors: Poverty, malnutrition, and limited education correlate with delayed diagnosis.

Diagnosis

Diagnosis combines clinical assessment with laboratory confirmation. Early diagnosis prevents nerve damage and transmission.

Clinical Examination

1. Detailed skin survey for characteristic lesions.
2. Palpation of peripheral nerves for thickening and tenderness.
3. Testing for sensation (cold, pain, light touch) using monofilament or cotton wisp.

Laboratory Tests

• Skin slit‑smear microscopy: Samples from active lesions stained with Ziehl‑Neelsen; a bacillary index (BI) of 1–5 is typical for borderline leprosy.
• Skin biopsy: Histopathology shows granulomas with variable numbers of acid‑fast bacilli; immunohistochemistry can aid classification.
• Polymerase chain reaction (PCR): Detects M. leprae DNA—useful when smear is negative.
• Serologic tests: Anti‑PGL‑1 antibody levels correlate with bacterial load but are not diagnostic alone.

Classification

The WHO classifies leprosy as:

• Paucibacillary (PB): ≤5 skin lesions, negative smear.
• Multibacillary (MB): >5 lesions or positive smear.

Borderline leprosy falls under the MB category because it usually shows a positive smear.

Treatment Options

Modern multidrug therapy (MDT) cures leprosy in >95 % of cases and halts transmission.

WHO‑Recommended MDT for Multibacillary Leprosy

Drug	Dosage	Frequency	Duration
Rifampicin	600 mg (adult)	Monthly, supervised	12 months (minimum)
Dapsone	100 mg	Daily, self‑administered	12 months (minimum)
Clofazimine	300 mg	Monthly supervised dose + 50 mg daily	12 months (minimum)

Adjunct Treatments

• Corticosteroids: Prednisone 0.5–1 mg/kg/day for acute neuritis or severe inflammation; taper over 4–6 weeks.
• Thalidomide: Reserved for refractory type‑II reactions (erythema nodosum leprosum) under strict pregnancy‑prevention protocols.
• Physiotherapy & orthoses: Prevent contractures and improve function.

Lifestyle & Supportive Measures

• Good skin hygiene and regular inspection of numb areas to avoid unnoticed injuries.
• Protective footwear to prevent foot ulcers.
• Nutrition optimisation (adequate protein, vitamins A, D, and B12).
• Psychosocial counseling to address stigma.

Living with Jerusalem Disease (Leprosy, Borderline Type)

Successful long‑term management hinges on adherence to therapy, regular monitoring, and community support.

Medication Adherence

• Take daily dapsone and clofazimine at the same time each day.
• Attend monthly supervised doses of rifampicin and clofazimine—these are observed by a health worker to ensure compliance.
• Report any side‑effects promptly (e.g., rash, liver dysfunction, hemolysis in G6PD‑deficient patients).

Self‑Care Practices

1. Inspect skin daily, especially anesthetic patches.
2. Keep affected areas clean and moisturised; avoid harsh soaps.
3. Use protective gloves when handling hot objects or sharp items.
4. Wear well‑fitting shoes; treat any foot ulcer immediately.
5. Engage in regular gentle stretching exercises to preserve joint mobility.

Psychosocial Aspects

• Join local leprosy support groups – peer interaction reduces isolation.
• Educate family members about the low infectivity after treatment begins (usually <7 days after first dose of rifampicin).
• Seek mental‑health counseling if you experience anxiety or depression related to stigma.

Follow‑Up Schedule

• Monthly clinic visits for the first 6 months, then every 3 months until completion of MDT.
• Neurological assessment at each visit to detect early neuritis.
• Skin smears repeated at 6‑month intervals if initial bacillary index was high.

Prevention

Because leprosy is not highly contagious, public‑health measures focus on early case detection and breaking transmission chains.

• Contact tracing: Examine household members and close contacts; give a single dose of rifampicin (SDR) as chemoprophylaxis when indicated.
• Vaccination research: The BCG vaccine offers modest protection (~20–30 %) against leprosy; routine BCG in endemic nations continues.
• Health education: Teach community signs of leprosy and the importance of prompt medical attention.
• Improved living conditions: Reduce crowding, enhance ventilation, and ensure access to clean water.

Complications

If left untreated or incompletely treated, borderline leprosy can progress to severe disability.

• Peripheral neuropathy: Permanent loss of sensation leading to repeated injuries, ulceration, and secondary infections.
• Physical deformities: Claw‑hand, foot drop, and facial nerve palsy that affect daily function.
• Eye involvement: Lagophthalmos, corneal ulceration, and blindness.
• Reactions:
  • Type‑1 (reversal) reaction – acute inflammation of existing lesions causing sudden nerve swelling.
  • Type‑2 (erythema nodosum leprosum) – painful nodules, fever, and systemic symptoms; can be life‑threatening.
• Social complications: Stigma, loss of employment, and mental‑health disorders.

When to Seek Emergency Care

References

1. World Health Organization. Global Leprosy (Hansen’s Disease) Situation Report 2023. WHO Press; 2024.
2. Mayo Clinic. Leprosy (Hansen Disease) – Symptoms and Causes. https://www.mayoclinic.org/diseases‑conditions/leprosy/symptoms‑causes
3. Cleveland Clinic. Leprosy (Hansen Disease) – Diagnosis and Treatment. https://my.clevelandclinic.org/health/diseases/16322-leprosy
4. National Institute of Allergy and Infectious Diseases (NIAID). Mycobacterium leprae. https://www.niaid.nih.gov/diseases‑conditions/leprosy
5. Centers for Disease Control and Prevention. Leprosy (Hansen Disease) – Laboratory Testing. https://www.cdc.gov/leprosy/lab-testing.htm
6. WHO. Guidelines for the Diagnosis, Treatment and Prevention of Leprosy, 2023. https://apps.who.int/iris/handle/10665/354585

```